Xenon Pharmaceuticals
Xenon Pharmaceuticals reported revenue of $8 million in fiscal 2025. Its operating margin was −4,974.3%. Free cash flow was −$280 million. The diluted share count rose 1.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Xenon Pharmaceuticals does
Xenon Pharmaceuticals is a biopharmaceutical company that develops drugs for neurological and psychiatric disorders. It has no products on the market. Its lead candidate, azetukalner, is a drug that opens Kv7 potassium channels in nerve cells, taken by mouth, and is in several Phase 3 studies, the last stage of testing before a company can ask regulators for approval.
Azetukalner is being tested in two kinds of epilepsy, focal onset seizures and primary generalized tonic-clonic seizures, and in major depressive disorder and bipolar depression. The company also has earlier-stage programs, including Kv7 potassium channel openers and Nav sodium channel modulators aimed at conditions such as pain.
Xenon does not sell any product and has no product revenue. Its strategy is to find drug candidates using its knowledge of how gene changes in ion channels cause disease, take selected ones through clinical studies, and either sell approved drugs itself or with partners. It may also bring in new candidates through acquisition or licensing, and it works with collaborators on some programs.
Its biggest risks, as it describes them
- It has lost money since it began and expects more losses, with no product sales yet.
- It will need more funding, which may not be available on acceptable terms and could dilute shareholders.
- Most of its hopes rest on azetukalner, which must succeed in late-stage studies and win approval.
- Competitors may develop or sell rival treatments before it does or do it better.
- Losing key executives and staff who run its studies and collaborations.
Income statement
Xenon Pharmaceuticals lost money in fiscal 2025: a net loss of $346 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 552 | 592 | 638 | 627 | 549 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 39.0x | 26.4x | 23.6x | 17.9x | 13.4x |
| Quick ratio | 39.0x | 26.4x | 23.6x | 17.9x | 13.4x |
Cash flow
Projections
Project Xenon Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Xenon Pharmaceuticals shares on the open market, and 6 insiders sold $22.0 million, $21.3 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Christopher John KenneyChief Medical Officer | Sold plan | 7,068 | $60.25 | $425,849 | Form 4 |
| Aug 11, 2026 | Steven GannonDirector | Sold | 10,000 | $64.06 | $640,600 | Form 4 |
| Jun 5, 2026 | Gary PatouDirector | Sold plan | 1,322 | $53.14 | $70,251 | Form 4 |
| Jun 5, 2026 | Gillian CannonDirector | Sold plan | 1,190 | $53.14 | $63,237 | Form 4 |
| Mar 13, 2026 | Ian MortimerPresident & CEO, Director | Sold plan | 7,308 | $55.23 | $403,621 | Form 4 |
| Mar 13, 2026 | Christopher John KenneyChief Medical Officer | Sold plan | 1,410 | $55.23 | $77,874 | Form 4 |
| Mar 13, 2026 | Andrea DiFabioChief Legal Officer | Sold plan | 1,342 | $55.23 | $74,119 | Form 4 |
| Mar 10, 2026 | Ian MortimerPresident & CEO, Director | Sold plan | 11,269 | $60.11 | $677,380 | Form 4 |
| Mar 10, 2026 | Christopher John KenneyChief Medical Officer | Sold plan | 2,771 | $60.11 | $166,565 | Form 4 |
| Mar 10, 2026 | Andrea DiFabioChief Legal Officer | Sold plan | 2,607 | $60.11 | $156,707 | Form 4 |
| Mar 9, 2026 | Ian MortimerPresident & CEO, Director | Sold plan | 270,000 | $60.33 | $16.3 million | Form 4 |
| Jan 2, 2026 | Ian MortimerPresident & CEO, Director | Sold plan | 40,000 | $44.43 | $1.8 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | 26.88 | 17.24 | 6.89 |
| Accruals ratio | −3.6% | −6.0% | −9.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | — | — | — |
Compare
Put Xenon Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals | FY25 | — | −4,974.3% | −3,732.2% | — | — | — | |
| Ovid Therapeutics | FY25 | 1,181.3% | −585.2% | −528.6% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
| Immunome | FY25 | −23.2% | −3,228.8% | −2,890.1% | — | — | — | Compare |
| Precigen | FY25 | 146.7% | −1,141.1% | −927.6% | — | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2 | 0 | — | 7 | 32 | 18 | 9 | 0 | 0 | 8 |
| Revenue growth | −88.4% | −82.8% | — | — | 371.0% | −42.7% | −48.8% | −100.0% | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 20 | 26 | 24 | 39 | 50 | 76 | 106 | 168 | 210 | 301 |
| Operating income | −25 | −33 | −38 | −43 | −31 | −79 | −129 | −214 | −279 | −373 |
| Net income | −23 | −31 | −34 | −42 | −29 | −79 | −125 | −182 | −234 | −346 |
| Diluted EPS (US$) | −1.48 | −1.72 | −1.63 | −1.54 | −0.81 | −1.77 | −2.06 | −2.73 | −3.01 | −4.36 |
| Diluted shares (millions) | 16 | 18 | 19 | 26 | 34 | 44 | 60 | 67 | 78 | 79 |
| Cash flow | ||||||||||
| Cash from operations | −20 | −29 | −35 | −5 | −48 | −70 | −101 | −151 | −181 | −279 |
| Capital expenditure | 0 | 0 | 0 | 1 | 3 | 2 | 3 | 6 | 3 | 1 |
| Free cash flow | −20 | −29 | −35 | −6 | −51 | −72 | −104 | −157 | −184 | −280 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 3 | 3 | 6 | 10 | 20 | 32 | 51 | 54 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 64 | 44 | 119 | 141 | 177 | 552 | 592 | 638 | 627 | 549 |
| Debt incl. finance leases | — | 7 | — | 16 | — | — | — | — | — | — |
| Total assets | 68 | 46 | 122 | 148 | 189 | 572 | 754 | 965 | 798 | 633 |
| Total liabilities | 4 | 10 | 19 | 56 | 18 | 22 | 33 | 37 | 43 | 51 |
| Shareholders' equity | 64 | 36 | 103 | 92 | 171 | 550 | 722 | 928 | 755 | 582 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −1,376.4% | −10,474.3% | — | −627.0% | −97.3% | −428.4% | −1,368.9% | — | — | −4,974.3% |
| Net margin | −1,275.5% | −9,872.7% | — | −609.1% | −89.7% | −427.9% | −1,329.0% | — | — | −4,612.1% |
| Free cash flow margin | −1,100.7% | −9,337.9% | — | −87.2% | −157.8% | −388.1% | −1,101.6% | — | — | −3,732.2% |
| Rule of 40 (growth + FCF margin) | −1,189.2% | −9,420.7% | — | — | 213.2% | −430.8% | −1,150.4% | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −36.8% | −61.5% | −49.5% | −42.6% | −21.9% | −21.9% | −19.7% | −22.1% | −27.9% | −51.8% |
| Return on assets | −35.0% | −54.0% | −40.9% | −30.8% | −17.1% | −20.7% | −18.9% | −21.2% | −26.6% | −48.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |